文献速递帕金森病与运动障碍神经重症与神经感染认知障碍与痴呆

唑吡坦治疗神经系统疾病:一项系统综述

Zolpidem for the Treatment of Neurologic Disorders: A Systematic Review.
PubMed 文献 · JAMA Neurol · 2017-01-01

该系统综述检索截至2015年3月20日的文献,纳入67篇使用唑吡坦治疗非失眠神经系统疾病的文章,涵盖运动障碍、意识障碍及其他疾病。研究发现唑吡坦可短暂改善多种神经系统症状,效果通常持续1至4小时,但多数证据来自病例报告和小型干预试验。

要点

  • 唑吡坦可能短暂改善运动障碍和意识障碍,效果持续1至4小时。
  • 现有证据多来自病例报告和小型试验,仅11项研究样本量超过10例。
  • 镇静是最常见的不良反应。

核心结论

  • 唑吡坦被观察到可短暂治疗多种神经系统疾病,最常与运动障碍和意识障碍相关。
  • 这些发现可能代表这些疾病的一种新治疗机制。

研究设计与样本

  • 系统综述检索PubMed、Scopus、Web of Science Core Collection、Cochrane Library、EMBASE、CENTRAL和clinicaltrials.gov,截至2015年3月20日。
  • 初检去重后得2314篇文章,经摘要筛选后67篇全文评估,最终纳入研究包括病例报告28项、病例系列8项、单患者干预13项、前后对照9项、随机临床试验9项和交叉研究5项。
  • 仅11项研究参与者超过10例。

主要发现

  • 31项研究治疗运动障碍,22项治疗意识障碍,14项治疗其他神经系统疾病包括卒中、创伤性脑损伤、脑病和痴呆。
  • 唑吡坦效果广泛,例如改善JFK昏迷恢复量表修订版、统一帕金森病评定量表和Burke-Fahn-Marsden肌张力障碍评定量表。
  • 效果通常持续1至4小时,之后参与者恢复至基线。
  • 镇静是最常见的不良反应。

临床怎么用

  • 唑吡坦可能作为运动障碍和意识障碍的短暂治疗选择,但需谨慎评估证据强度。
  • 临床使用时应注意效果短暂和镇静的不良反应。

局限性

  • 多数已知信息来自病例报告和小型干预试验。
  • 仅11项研究参与者超过10例,证据等级有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Given its selective action on the ω1 subtype of the γ-aminobutyric acid A receptor, zolpidem tartrate presents a potential treatment mechanism for other neurologic disorders. OBJECTIVE: To synthesize studies that used zolpidem to treat neurologic disorders. EVIDENCE REVIEW: Eligibility criteria included any published English-language article that examined the use of zolpidem for noninsomnia neurologic disorders in humans for all dates up to March 20, 2015. Searched databases included PubMed, Scopus, Web of Science Core Collection, the Cochrane Library, EMBASE, CENTRAL, and clinicaltrials.gov. Publication bias was mitigated by searching clinicaltrials.gov for unpublished studies. Two rounds of screening were performed based on title and then abstract, and coding was performed by 2 coders. All methods followed the PRISMA Reporting Guidelines for systematic reviews of the literature. FINDINGS: The initial search produced 2314 articles after removing duplicates. After exclusion based on a review of abstracts, 67 articles remained for full manuscript review. Thirty-one studies treated movement disorders, 22 treated disorders of consciousness, and 14 treated other neurologic conditions, including stroke, traumatic brain injury, encephalopathy, and dementia. Study designs included case reports (n = 28), case series (n = 8), single-patient interventional (n = 13), pretest and posttest (n = 9), randomized clinical trials (n = 9), and crossover studies (n = 5). Only 11 studies had more than 10 participants. Effects of zolpidem were wide ranging (eg, improvement on the JFK Coma Recovery Scale-Revised, the Unified Parkinson Disease Rating Scale, and the Burke-Fahn-Marsden Dystonia Rating Scale) and generally lasted 1 to 4 hours before the participant returned to baseline. Sedation was the most common adverse effect. CONCLUSIONS AND RELEVANCE: Zolpidem has been observed to transiently treat a large variety of neurologic disorders, most often related to movement disorders and disorders of consciousness. Much of what is known comes from case reports and small interventional trials. These findings may represent a new treatment mechanism for these disorders.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Bomalaski MN, Claflin ES, Townsend W, et al. Zolpidem for the Treatment of Neurologic Disorders: A Systematic Review. JAMA Neurol. 2017. PMID: 28655027. doi:10.1001/jamaneurol.2017.1133

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。